search
Back to results

Reducing Isolation and Feeling of Loneliness During Critical Illness (SOCIAL)

Primary Purpose

Critical Illness, Social Isolation, Anxiety

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Social Engagement
Sponsored by
Kirby Mayer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Critical Illness focused on measuring critical illness, Post Intensive Care Unit Syndrome, social isolation

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adult
  • admitted to ICU with acute respiratory failure (ventilation via tube or mask or HFNC)

Exclusion Criteria:

  • previous cognitive or emotional health condition
  • inability to follow commands

Sites / Locations

  • UK Heatlhcare

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Social engagement using VR

Control

Arm Description

Patients will receive social engagement with emphasize on meaningful conversation, cognitive engagement, and emotional support provided by trained research assistant using virtual reality as a vehicle for delivery. Subjects will receive 15-45 minutes of treatment per day for 5 days initiated after respiratory support (Intubation via mask or tube, high-flow nasal cannula) have been weaned to nasal cannula. Experimental group will also receive standard of care

Control will receive standard of care

Outcomes

Primary Outcome Measures

Feasibility of implementing the study intervention
Determine the number of sessions delivered per number of sessions scheduled. The study sample size of 12 subjects to receive the intervention, and each subject in the intervention should receive 5 sessions each = 60 sessions total; success will be considered 75% of sessions delivered (45 sessions completed of 60 planned).
Safety of the study intervention defined as number of patients with treatment-related adverse event
Minor adverse events, major adverse events, and unanticipated problems as assessed by the investigators per study protocol will be recorded during each treatment session. The rate of adverse events will be examined.

Secondary Outcome Measures

Self-reported anxiety
Hospital Anxiety and Depression Scale - Anxiety- self report questionnaire with higher scores indicating worse perceived anxiety
Self-reported depression
Hospital Anxiety and Depression Scale - Depression - self report questionnaire with higher scores indicating worse perceived depression
Self-reported health related quality of life
EurQol-5Domain (EQ-5D) - self report questionnaire with higher scores indicating better perceived quality of life
Cognitive function
Montreal Cognitive Assessment - performed cognitive examination with higher scores indicating better cognitive function

Full Information

First Posted
July 27, 2022
Last Updated
July 13, 2023
Sponsor
Kirby Mayer
search

1. Study Identification

Unique Protocol Identification Number
NCT05537311
Brief Title
Reducing Isolation and Feeling of Loneliness During Critical Illness
Acronym
SOCIAL
Official Title
Reducing Isolation and Loneliness in Patients With Critical Illness With Novel Engagement Strategies: a Pilot Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
July 27, 2022 (Actual)
Primary Completion Date
July 1, 2023 (Actual)
Study Completion Date
July 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Kirby Mayer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The trial is a pilot-randomized trial testing feasibility and limited-efficacy of delivering social engagement using technologic strategies to reduce periods of social isolation.
Detailed Description
Patients with critical illnesses such as sepsis and acute respiratory failure (ARF) who require an ICU stay are at high risk of developing anxiety, depression, post-traumatic stress disorder, and cognitive deficits. Risk factors for emotional and cognitive impairments after ICU include underlying systematic illness, as well as consequences of life-saving therapies. In brief, patients are frequently restricted and even restrained to the bed, provided high dosages of sedatives, develop delirium, and are isolated from family and staff for extended periods of time. Moreover, the ICU environment including lights, noises, and the social isolation have a serious negative impact on cognitive function and emotional health status. Prospective data from the ICU demonstrate that critically ill patients in ICU spend two-thirds of their time completely alone. Patients who have survived describe their ICU experience as a traumatic event similar to war, and testimonials for the ICU Recovery clinic frequently resemble: "I felt like I was being held captive in an unknown basement." Periods of social isolation in daily life as well as in the hospital have a significant negative impact on patient-centered outcomes including increased risk of disability, frailty, and mortality. Our study will examine the feasibility of delivering social engagement interventions using technology such as virtual reality (VR) to reduce feelings of isolation and loneliness. There have been a handful of projects to reduce anxiety and depression using a myriad of delivery techniques including journaling in a diary, emotional-behavioral therapy, face-to-face social engagement and family engagement using face-time and VR. These projects, however, have not examined the impact of social engagement on reducing periods of isolation and loneliness. We hypothesize that social engagement delivered using VR technologies will reduce periods of social isolation and thus improve anxiety, depression, and post-traumatic stress disorder (PTSD).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness, Social Isolation, Anxiety, Depression, Post Intensive Care Unit Syndrome
Keywords
critical illness, Post Intensive Care Unit Syndrome, social isolation

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
pilot-randomized trial
Masking
Outcomes Assessor
Masking Description
Outcome assessor will be blinded to treatment group
Allocation
Randomized
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Social engagement using VR
Arm Type
Experimental
Arm Description
Patients will receive social engagement with emphasize on meaningful conversation, cognitive engagement, and emotional support provided by trained research assistant using virtual reality as a vehicle for delivery. Subjects will receive 15-45 minutes of treatment per day for 5 days initiated after respiratory support (Intubation via mask or tube, high-flow nasal cannula) have been weaned to nasal cannula. Experimental group will also receive standard of care
Arm Title
Control
Arm Type
No Intervention
Arm Description
Control will receive standard of care
Intervention Type
Behavioral
Intervention Name(s)
Social Engagement
Intervention Description
30-45 minutes of social engagement provided to patients in ICU. Social engagement strategies including meaningful conversation, cognitive stimulation, and emotional support
Primary Outcome Measure Information:
Title
Feasibility of implementing the study intervention
Description
Determine the number of sessions delivered per number of sessions scheduled. The study sample size of 12 subjects to receive the intervention, and each subject in the intervention should receive 5 sessions each = 60 sessions total; success will be considered 75% of sessions delivered (45 sessions completed of 60 planned).
Time Frame
Through completion of the intervention, which on average will occur one week after randomization
Title
Safety of the study intervention defined as number of patients with treatment-related adverse event
Description
Minor adverse events, major adverse events, and unanticipated problems as assessed by the investigators per study protocol will be recorded during each treatment session. The rate of adverse events will be examined.
Time Frame
Through completion of the intervention, which on average will occur one week after randomization
Secondary Outcome Measure Information:
Title
Self-reported anxiety
Description
Hospital Anxiety and Depression Scale - Anxiety- self report questionnaire with higher scores indicating worse perceived anxiety
Time Frame
Through study completion, which will occur on average 1-3 months after hospital discharge
Title
Self-reported depression
Description
Hospital Anxiety and Depression Scale - Depression - self report questionnaire with higher scores indicating worse perceived depression
Time Frame
Through study completion, which will occur on average 1-3 months after hospital discharge
Title
Self-reported health related quality of life
Description
EurQol-5Domain (EQ-5D) - self report questionnaire with higher scores indicating better perceived quality of life
Time Frame
Through study completion, which will occur on average 1-3 months after hospital discharge
Title
Cognitive function
Description
Montreal Cognitive Assessment - performed cognitive examination with higher scores indicating better cognitive function
Time Frame
Through study completion, which will occur on average 1-3 months after hospital discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adult admitted to ICU with acute respiratory failure (ventilation via tube or mask or HFNC) Exclusion Criteria: previous cognitive or emotional health condition inability to follow commands
Facility Information:
Facility Name
UK Heatlhcare
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
IPD will be shared via dissemination at national conferences and manuscripts; and available upon request of the primary investigator

Learn more about this trial

Reducing Isolation and Feeling of Loneliness During Critical Illness

We'll reach out to this number within 24 hrs